From: Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers
Cancers | Proteins | SNP | Unipoint | OR (95%) | P | PVE (%) | Steiger filtering | Bidirectional MR P-value (IVW/MR-egger) | F |
---|---|---|---|---|---|---|---|---|---|
Prostate cancer | KDELC2 | rs74911261 | Q7Z4H8 | 0.89 (0.86, 0.93) | 1.89E−08 | 8.61 | 8.23E−60 | 0.189b | 310.89 |
SPINT2 | rs71354995 | A0A140VJV6 | 1.05 (1.03, 1.06) | 1.49E−06 | 36.59 | NA | 0.231b | 1905.11 | |
TNFRSF10B | rs4871844 | O14763 | 0.74 (0.65, 0.83) | 2.41E−07 | 0.94 | 3.19E−06 | 0.228b | 30.25 | |
GSTP1 | rs1695 | P09211 | 0.82 (0.74, 0.90) | 1.82E−05 | 1.47 | 3.14E−10 | 0.337b | 49.17 | |
IGF2R | rs629849 | P11717 | 0.92 (0.90, 0.94) | 4.57E−10 | 18.27 | 7.55E−138 | 0.026b | 738 | |
CTSS | rs41271951 | P25774 | 0.91 (0.88, 0.95) | 2.56E−07 | 11.33 | 2.24E−81 | 0.806b | 421.77 | |
HDGF | rs4399146 | P51858 | 1.14 (1.07, 1.21) | 5.73E−05 | 3.01 | 3.62E−20 | 0.015b | 99.26 | |
Breast cancer | CPNE1 | rs12481228 | Q99829 | 0.96 (0.94, 0.98) | 5.15E−05 | 16.76 | 1.24E−130 | 0.979b | 664.52 |
PDIA3 | rs3110081 | P30101 | 1.19 (1.10, 1.30) | 3.20E−05 | 1.14 | 3.39E−08 | 0.315b | 36.75 | |
GDI2 | rs2890364 | P50395 | 0.85 (0.80, 0.91) | 3.34E−06 | 1.75 | 4.19E−12 | 0.598b | 57.03 | |
ISLR2 | rs2959011 | Q6UXK2 | 0.87 (0.82, 0.93) | 4.27E−05 | 1.71 | 2.19E−12 | 0.336b | 57.55 | |
CTSF | rs1791679 | Q9UBX1 | 1.14 (1.08, 1.21) | 7.53E−06 | 2.26 | 5.40E−16 | 0.245b | 76.25 | |
Lung cancer | SFTPB | rs1130866 | P07988 | 0.93 (0.91, 0.95) | 6.36E−09 | 46.61 | 3.77E−178 | 0.771b | 972.31 |
CTSH | rs34593439 | P09668 | 1.07 (1.05, 1.10) | 1.71E−08 | 49.95 | 1.07E−199 | 0.002a | 1098.94 | |
ICAM5 | rs281439 | Q8N6I2 | 0.95 (0.93, 0.97) | 2.94E−05 | 53.15 | 9.08E−219 | 0.217b | 1194.8 | |
FLRT3 | rs11908097 | Q9NZU0 | 1.10 (1.05, 1.15) | 2.16E−05 | 14.37 | 2.90E−50 | 0.217b | 255.54 |